[Application of a new compact and cell dense continuous culture system for LAK cells generated from cryo-preserved lymphocytes]
- PMID: 2351852
[Application of a new compact and cell dense continuous culture system for LAK cells generated from cryo-preserved lymphocytes]
Abstract
Recently, the adoptive immunotherapy using lymphokine activated killer (LAK) cells has been applied for various cancer patients. It is quite useful to generate LAK cells from cryo-preserved lymphocytes in order to make a rational treatment schedule. We made basic studies on the induction of LAK cells from frozen lymphocytes using our high yield continuous cell culture system. It was demonstrated that our culture bag can be used to proliferate frozen lymphocytes cultured in interleukin-2 (IL-2) to thirty four-fold the initial cell number in 14 days with comparable cytotoxicity to that of fresh lymphocytes cultured in the same system.
Similar articles
-
A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.J Clin Lab Immunol. 1990 May;32(1):41-7. J Clin Lab Immunol. 1990. PMID: 1967036
-
Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.Cancer Res. 1991 May 1;51(9):2324-8. Cancer Res. 1991. PMID: 2015597
-
Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.Cancer Res. 1990 Nov 15;50(22):7343-50. Cancer Res. 1990. PMID: 2224862 Clinical Trial.
-
Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.J Immunol. 1987 Apr 15;138(8):2728-33. J Immunol. 1987. PMID: 2435804
-
Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.APMIS Suppl. 1995;55:1-28. APMIS Suppl. 1995. PMID: 8534522 Review.